Daiichi Sankyo to expand access to clinical trial data
pharmafile | February 3, 2016 | News story | Research and Development | Daiichi Sankyo, R&D, clinical trials, open access, open data, transparency
Daiichi Sankyo has announced today that it will share clinical trial data to qualified researchers through an online web request system.
From today, qualified researchers can submit research proposals through a web portal, at clinicalstudydatarequest.com, requesting data from Daiichi Sankyo-sponsored trials for approved medicines in the EU and US. Daiichi Sankyo will provide data from its trials of approved medicines and indications conducted from January 2014 onward. Access is mediated by an independent review panel.
The move is to promote more data sharing and openness with the industry and biopharma researchers. The Japanese firm says it is “committed to disclose information from the clinical trials it sponsors” and “recognises that there are important benefits associated with making clinical trial information available.”
Once a qualified request is approved by the independent panel, and deemed clear of restrictions, Daiichi Sankyo will anonymise the information to protect patient privacy, and will make requested analyses available in a secure electronic environment. The pharma company will be responsible for making sure that all applicable laws and regulations are adhered to throughout the process.
Dr Mahmoud Ghazzi, global head of development for Daiichi Sankyo, adds: “Sharing clinical data from trials sponsored by Daiichi Sankyo with qualified researchers helps foster additional scientific insights and provides a mechanism for further understanding of our medicines, which ultimately is a benefit to patient healthcare.”
Lilian Anekwe
Related Content
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
Gilead and Merck share data from phase 2 trial of HIV treatment
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …
